NeurologyWire

AbbieVie Receives Approval for Carbidopa and Levodopa Pump

From NeurologyWire

FDA has approved Duopa (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's disease. Duopa is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine for 16 continuous hours via a procedurally-placed tube.It was appr...

Login to read story

Thursday, March 05, 2015

Show last days of articles

Cerebral Blood Flow as a Possible Marker for Concussion Outc...

From NeurologyWire

A new imaging study suggests that cerebral blood flow recovery in the brain could be a biomarker of outcomes in patients following concussion, accordi...Full story

One-third of Americans Do Not Have Access to Stroke Center W...

From NeurologyWire

One-third of the US population does not have access to a primary stroke center within one hour by ambulance, and even under optimal conditions, a larg...Full story

NIH-led Effort Launches Big Data Portal for Alzheimers Drug ...

From NeurologyWire

A National Institutes of Health-led public-private partnership has launched the new Alzheimers Big Data portal including delivery of the first wave o...Full story

Wednesday, March 04, 2015

FDA Requires Label Change for Testosterone Products

From NeurologyWire

FDA is requiring manufacturers of testosterone products make label changes about a possible increased risk of heart attacks and strokes in patients ta...Full story

Tuesday, March 03, 2015

FDA Agrees to Review Xadago (safinamide) as Add-on Therapy f...

From NeurologyWire

FDA has accepted the New Drug Application (NDA) for Xadago (safinamide), and will be reviewed as an add-on therapy for patients with early- to late-st...Full story

Monday, March 02, 2015

The Sobering Effect of Oxytocin

From NeurologyWire

Oxytocin, sometimes referred to as the love or cuddle hormone, has a legendary status in popular culture due to its vital role in social and sexual be...Full story

New Compounds Protect Nervous System From the Structural Dam...

From NeurologyWire

A newly characterized group of pharmacological compounds block both the inflammation and nerve cell damage seen in mouse models of multiple sclerosis,...Full story

FDA Rejects Pacira's Application for Expanded Use of Pain Dr...

From NeurologyWire

FDA rejected Pacira Pharmaceuticals Inc's application for expanding the use of its post-surgery pain drug, Exparel. The drug is currently injected int...Full story

New Drug Candidate for Alzheimer's to Begin Trials This Year

From NeurologyWire

Alkermes formally introduced the new drug candidate for the treatment of agitation in patients with Alzheimers disease, major depressive disorder (MDD...Full story

Friday, February 27, 2015

Coffee Might Lower Risk of MS

From NeurologyWire

Drinking coffee may be associated with a lower risk of developing multiple sclerosis (MS), according to a study released today that will be presented ...Full story

Thursday, February 26, 2015

How to Tell If Your Child Experiences Migraine

From NeurologyWire

To help parents identify potential migraine warning signs in their kids and get them evaluated (and treated, if necessary), the American Migraine Foun...Full story

Parkinson's Patients Have Reduced Visual Contrast Acuity

From NeurologyWire

Patients with Parkinson's disease (PD) often have difficulties with visual acuity in low-contrast images. Because they may have normal high-contrast v...Full story

Wednesday, February 25, 2015

Minimally Invasive Tumor-Fighting Tool Treats First Patient ...

From NeurologyWire

The NeuroBlate System, a minimally invasive robotic laser thermotherapy tool, has been used for the first time following Health Canada Licensing late ...Full story

Tuesday, February 24, 2015

FDA OKs Neuronetrix Portable EEG device

From NeurologyWire

FDA has has given the green light to Neuronetrix's portable device for the recording of electrical brainwaves in patients with neurological conditions...Full story

Positive Results in Phase IIb Chronic Migraine Study

From NeurologyWire

Teva released positive results from a Phase IIb study evaluating the efficacy, safety and tolerability of two doses of subcutaneous TEV-48125, an inve...Full story